Market Gap Narrows and It’s Time to Put Cash to Work
The AI complex is getting hit on earnings while small caps, biotech, retail and defensive pharma hold up. Here’s what I’m buying.
Amid the Biotech Madness, I Spotted an Opening in a Promising Small-Cap
Hedge funds dumped genomics plays like this one last week … but it was just as it announced a new AstraZeneca-linked deal.
Psst: These Two Biotech Plays Look Like Great Under-the-Radar Deals
Let’s check out two biopharma plays that scream ‘growth at a reasonable price.’
How to Trade This Cash-Rich Biopharma Name
This weekend’s covered call idea is around a cash-rich biopharma concern that is expecting a key FDA approval to close out 2026.
Three Biotechs Bolstered by Positive News
Biotech has been a market laggard lately, but I’m eyeing three companies making recent progress.
Amid a Lack of Market Leadership, I’m Eyeing These 2 Stocks
I’m adding to this oil play and biopharma stock as market sees some strange and broad-but-shallow action Tuesday.
One of My Top Small-Cap Biotech Picks Made a Move. Here’s How I Trade It
The FDA just granted this biopharma name a key designation. Let me show you in detail how I handle a stock like this.
After Moderna’s Big News, Here Are Three Biotechs to Watch
I’m following these lesser-known names amid biopharma’s move on Wednesday.
I See Two Very Different Opportunities in This Overbought Market
I’m getting into a legacy technology stock and an up-and-coming biopharma. Here’s why.
As Market Sorts Out AI, I’m Playing 2 Small-Cap Biotechs
I’ve got two biopharma stocks on my radar ahead of earnings.